Vera Buerger

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®).

Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®).

Journal: Vaccine
Published: February 16, 2026

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.

Journal: Nature medicine
Published: July 07, 2025

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil.

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil.

Journal: The Lancet. Infectious diseases
Published: June 02, 2025

Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ®).

Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ®).

Journal: Vaccines
Published: March 31, 2025

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.

Journal: Emerging microbes & infections
Published: February 25, 2025

Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.

Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.

Journal: Journal of travel medicine
Published: July 31, 2024

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.

Journal: Vaccines
Published: July 06, 2024

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.

Journal: The Lancet. Infectious diseases
Published: May 16, 2024

Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.

Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.

Journal: Journal of travel medicine
Published: May 01, 2024

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.

Journal: The Lancet. Infectious diseases
Published: March 19, 2024

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.

Journal: Journal of travel medicine
Published: October 12, 2023

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)
Published: October 25, 2022
Showing 1-12 of 13

Last Updated: 09/26/2026